Clostridium difficile infection future or investigational therapies
|
Clostridium difficile Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Clostridium difficile infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Clostridium difficile infection future or investigational therapies |
|
FDA on Clostridium difficile infection future or investigational therapies |
|
CDC on Clostridium difficile infection future or investigational therapies |
|
Clostridium difficile infection future or investigational therapies in the news |
|
Blogs on Clostridium difficile infection future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future or Investigational Therapies
On December 14, 2005, researchers at McGill University in Montreal, Quebec, led by Dr. Ken Dewar and Dr. Andre Dascal and in collaboration with province-organized NPO Genome Quebec's research facility, announced they had cracked the genetic code of the highly virulent Quebec strain of C. difficile. This was accomplished by using ultra high-throughput sequencing technology. The tests involved doing 400,000 DNA parallel sequencing reactions which took the bacterium's genome apart and reassembled it so it could be studied.[1][2]
It is expected this will allow quicker detection of the disease and better treatment.
References
- ↑ Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S, Bourgault A, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson T, Horn R, René P, Monczak Y, Dascal A (2005). "A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality". N Engl J Med. 353 (23): 2442–9. PMID 16322602.
- ↑ Scientists map C. difficile strain - Institute of Public Affairs, Montreal